Sales and Revenue - The total sales amount from the top five customers is ¥165,412,462.81, accounting for 5.35% of the annual total sales[1]. - The company's revenue for 2022 was CNY 3,092,864,688.21, representing a 12.46% increase from CNY 2,750,202,059.34 in 2021[76]. - Quarterly revenue for Q4 2022 reached CNY 1,221,899,498.11, contributing to the overall annual growth[77]. - The revenue from healthcare information technology business accounted for 81.75% of total revenue, with a year-on-year growth of 9.40%[108]. - The internet healthcare business revenue grew by 28.38%, accounting for 18.21% of total revenue[108]. - The revenue from software products was CNY 265.83 billion, representing a year-on-year increase of 9.9%[89]. - The revenue from information technology services was CNY 701.28 billion, with a year-on-year growth of 11.7%[89]. - The company achieved operating revenue of 3,092.86 million yuan, a year-on-year increase of 12.46%[108]. - The revenue from hardware sales was approximately ¥459.21 million, with a gross margin of 11.17%[120]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[177]. Expenses and Costs - Sales expenses increased by 28.10% year-on-year, totaling ¥495,871,530.24 in 2022[2]. - R&D expenses rose by 22.73% year-on-year, amounting to ¥313,773,819.41 in 2022[2]. - The company's main business costs for 2022 amounted to 1,234,582,227.79 yuan, representing 70.89% of total operating costs, compared to 1,079,886,962.74 yuan and 73.19% in 2021, reflecting a year-on-year increase of 14.33%[48]. - Software development labor costs were 306,785,778.95 yuan, accounting for 17.62% of operating costs, up from 15.15% in 2021, marking a 37.26% increase[48]. - Hardware material costs reached 407,902,261.69 yuan, which is 23.42% of operating costs, compared to 26.02% in the previous year, with a year-on-year increase of 6.24%[48]. - Technical service labor costs were 153,438,165.94 yuan, making up 8.81% of operating costs, slightly down from 9.13% in 2021, with a year-on-year increase of 13.88%[48]. - The gross margin for the healthcare information technology sector was reported at 51.17%, a decrease of 2.11% compared to the previous year[120]. - The gross margin improved to 45%, up from 42% in the previous year, indicating better cost management[177]. Research and Development - The number of R&D personnel increased by 9.90% to 2,487 in 2022[7]. - R&D investment reached ¥625,518,769.72 in 2022, accounting for 20.22% of operating revenue[7]. - The proportion of capitalized R&D expenses to total R&D investment is 49.84% in 2022[7]. - The company is currently working on six major R&D projects aimed at enhancing product competitiveness[7]. - The company reported a total R&D capitalization amount of ¥278,299,228.09 for the development of next-generation smart medical products and cloud services, which are currently in progress[10]. - The company invested ¥625 million in R&D, accounting for 20.22% of total revenue, and obtained 47 new patents during the reporting period[114]. Cash Flow and Investments - Operating cash inflows for 2022 reached ¥3,456,104,778.63, representing a year-on-year increase of 15.51%[14]. - The net cash flow from operating activities decreased by 72.71% to ¥100,441,940.18, primarily due to increased cash payments to employees[14]. - The investment activities generated a net cash outflow of ¥349,790,906.68, reflecting a slight increase in outflows compared to the previous year[14]. - The company incurred an investment loss of ¥65,675,691.37, accounting for -170.41% of total profit, indicating significant challenges in investment performance[15]. - The total investment amount for the reporting period was ¥160,630,100, a decrease of 65.74% compared to ¥468,916,000 in the same period last year[29]. Profitability - In 2022, the company achieved a net profit attributable to shareholders of 108.44 million yuan, a decrease of 71.33% year-on-year[48]. - The net profit attributable to shareholders for 2022 was CNY 108,436,489.10, a decrease of 71.33% compared to CNY 378,174,115.45 in 2021[76]. - The basic earnings per share for 2022 was CNY 0.0507, a decline of 71.27% from CNY 0.1765 in 2021[76]. - The net profit attributable to shareholders of the listed company was approximately CNY 31.76 million, a decrease of 31.6% compared to the previous period[79]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 30.57 million, down 20.4% year-on-year[79]. Market and Industry Trends - The software and information technology service industry in China saw a revenue growth of 11.2% year-on-year, reaching CNY 1,081.26 billion in 2022[89]. - As of 2022, there are over 1,700 internet hospitals in China, with online medical user numbers exceeding 300 million, reflecting a significant increase in demand for online consultations and services[97]. - The "14th Five-Year" plan emphasizes the promotion of hospital information system cloud deployment, which is expected to enhance operational efficiency and data sharing capabilities[97]. - The integration of artificial intelligence in medical applications is being accelerated, with seven key scenarios identified for exploration, including intelligent diagnostic support and smart hospital management[93]. - The demand for data-driven systems and platforms in hospitals is increasing, as there is a need to unlock the value of accumulated data for clinical, research, and management purposes[97]. Strategic Initiatives - The company plans to focus on new product development and market expansion strategies in the upcoming year[68]. - The company is focusing on expanding its cloud services for healthcare institutions, including medical cloud and community cloud offerings[10]. - The company continues to invest in the WiNEX series products and the "Internet + Healthcare" innovation and market expansion, driven by technological innovation[48]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a target of 500 million RMB in potential acquisitions[177]. - The company plans to enhance its digital marketing strategy, aiming for a 30% increase in online sales[177].

Order and Market Overview - In the first half of 2023, the order amount saw a slight increase compared to last year, with 21 projects exceeding 10 million [3]. - New customer acquisition in the first half of 2023 included 61 new clients contributing a contract amount of 332 million CNY, compared to 60 clients and 292 million CNY in the same period of 2022 [4]. Strategic Developments - The WiNEX design concept aligns with the future development direction of hospital information systems and has innovated in advanced technology fields [6]. - The company has made significant breakthroughs in strategic areas, including the establishment of integrated platforms and data centers to enhance connectivity and improve medical services [7]. Product and Service Enhancements - The WiNEX product line has undergone iterative upgrades, integrating over 50 external systems and enhancing core system capabilities [16]. - The introduction of a unified data service aims to provide standard data services for clinical systems and operational management [8]. Healthcare Ecosystem and Community Initiatives - The company is advancing the construction of healthcare community information systems across more than 60 county-level medical communities in various provinces [9]. - A comprehensive solution for healthcare communities has been developed, covering platforms, hospitals, and grassroots institutions [9]. Interoperability and Smart Hospital Evaluation - A total of 85 hospitals have achieved interoperability ratings of four stars or above, while 30 hospitals have reached five-star ratings for electronic medical records [10]. - The company has implemented a series of tools to enhance the delivery of services, including user research platforms and data governance tools [24]. AI and Data Utilization - The WiNGPT model has been developed to enhance decision-making capabilities through structured analysis of medical records, improving risk monitoring accuracy [44]. - The integration of AI technologies aims to streamline processes such as automatic report generation and patient health assistance [38][40]. Financial and Operational Management - The company has invested in comprehensive hospital operational management solutions, covering various aspects from human resources to financial analysis [12]. - It has established a strong presence in the medical insurance sector, focusing on digital risk control solutions and compliance monitoring [13]. Future Collaborations and Research - Recent strategic partnerships have been formed to enhance digital healthcare research and the development of generative AI models for medical applications [14]. - The company is committed to building a robust ecosystem for big data and AI in healthcare, collaborating with various institutions for knowledge sharing and resource management [14].

证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------------|---------------|-------------|----------------| | | | | 编号：2023-004 | | 投资者关系活动类 | √特定对象调研 | □分析师会议 | | 别□媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（请文字说明其他活动内容） | --- | --- | |--------------|--------------------------------------------------------------------------------------------------------------------------------| | 参与单位名称 | APS（毕盛资产）、Aspex Management（思柏投资）、LMR Partners、Tokio Marine Asset Management（东京海上国际资管）、Morgan ...

证券代码：300253 证券简称：卫宁健康 卫宁健康科技集团股份有限公司 投资者关系活动记录表 编号：2023-003 | 投资者关系活 | □特定对象调研 分析师会议 □ | | --- | --- | | 动类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称 | 投资者网上提问 | | 及人员姓名 | | | 时间 | 年 月 日 2023 4 27 (周四) 下午 15:00~17:00 | | 地点 | 公司通过 全景网" 投 资 者 关 系 互 动 平 台 " | | | （https://ir.p5w.net）采用网络远程的方式召开业绩说明 | | | 会 | | 上市公司接待 | 董事长：周炜先生 | | 人员姓名 | 董事、高级副总裁、董事会秘书：靳茂先生 | | | 独立董事：王蔚松先生 | | | 财务总监：王利先生 | | | 保荐代表人：樊愈波先生 | | | 投资者提出的问题及公司回复情况 | | | 1、董秘先生，今天的业绩说明上多次提人力资源压力大， | ...

证券代码：300253 证券简称：卫宁健康 公告编号：2023-048 卫宁健康科技集团股份有限公司关于 参加 2023 年上海辖区上市公司年报集体业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 欢迎广大投资者积极参与。 特此公告。 卫宁健康科技集团股份有限公司 董 事 会 二〇二三年四月二十七日 为进一步加强与广大投资者的沟通交流，卫宁健康科技集团股份 有限公司（以下简称"公司"）将参加"2023年上海辖区上市公司年 报集体业绩说明会"活动，现将有关事项公告如下： 本次业绩说明会活动将采取网络的方式举行，投资者可以登录 "上证路演中心"网站（ http://roadshow.sseinfo.com ）或关注 微信公众号上证路演中心参与活动，活动时间为2023年5月10日（周 三）15:00至17:00。 届时公司的董事长周炜先生，董事、高级副总裁、董事会秘书靳 茂先生，财务总监王利先生，将通过网络在线交流形式与投资者就公 司治理、发展战略、经营状况、融资计划、股权激励和可持续发展等 投资者关注的问题进行沟通。 ...

Financial Performance - Total operating revenue for Q1 2023 was CNY 449,172,857.10, a slight increase from CNY 445,524,588.55 in Q1 2022, representing a growth of approximately 0.37%[6] - The company reported a net loss of ¥90,204,109.26 for the current period, compared to a net profit of ¥13,823,046.52 in the previous period[8] - Operating profit was recorded at -¥108,073,141.09, a significant decline from the previous operating profit of ¥23,204,986.50[8] - The net profit attributable to shareholders of the listed company is CNY -63,534,739.90, a decrease of 300.02% from CNY 31,763,439.87 in the previous year[22] - The total comprehensive income attributable to the parent company was -¥63,534,739.90, a decrease from ¥31,763,439.87 in the prior period[8] Operating Costs and Expenses - Total operating costs increased significantly to CNY 585,423,433.04 from CNY 460,944,963.89, marking an increase of about 27.0%[6] - Research and development expenses rose to CNY 94,566,268.35, up from CNY 66,198,838.64, reflecting a growth of approximately 42.9%[6] - The company's financial expenses increased by 62.16% compared to the same period last year, mainly due to a decrease in interest income[40] - The company's credit impairment losses increased by 61.85% year-on-year, reflecting a rise in bad debt provisions for accounts receivable[40] Assets and Liabilities - The total assets decreased to CNY 7,743,296,274.77 from CNY 7,821,828,010.96, a decline of about 1.0%[5] - Total liabilities decreased to CNY 2,652,001,850.22 from CNY 2,695,151,070.75, a reduction of approximately 1.6%[5] - The total liabilities and equity amounted to CNY 7,743,296,274.77, down from CNY 7,821,828,010.96, reflecting a decrease of approximately 1.0%[5] - The equity attributable to shareholders of the parent company increased slightly to CNY 5,119,636,812.60 from CNY 5,109,840,517.67, showing a growth of about 0.2%[5] Cash Flow - Cash flow from operating activities showed a net outflow of -¥92,026,081.61, improving from -¥98,677,812.85 in the previous period[12] - The company incurred a total cash outflow of ¥713,000,427.35 in operating activities, compared to ¥707,899,338.05 last year[12] - The net cash flow from operating activities is CNY -92,026,081.61, showing an improvement of 6.74% compared to CNY -98,677,812.85 in the same period last year[22] Revenue Breakdown - The revenue from the core medical health information business grew by 3.73%, while software sales and technical services revenue decreased by 1.62%[44] - The hardware sales revenue increased by 36.35% year-on-year[44] - The internet medical health business revenue declined by 12.73% year-on-year[44] - Total revenue from operating activities was ¥620,974,345.74, slightly up from ¥609,221,525.20 in the prior period[12] Investments and Projects - The company has completed the investment of CNY 49 million in the new generation smart medical product development and cloud service project, achieving 100% usage progress[54] - The company has confirmed CNY 712.46 million used in the new generation smart medical product development project in the first quarter of 2023[54] - The company has invested CNY 3,918.88 million in the drug supply chain management project, achieving a usage progress of 30.73%[54] - The company has allocated CNY 9.28651 million from the remaining fundraising for the drug supply chain management project to supplement working capital permanently[54] Shareholder Information - The company’s diluted earnings per share were reported at -¥0.0294, compared to ¥0.0148 in the previous period[8] - The company raised ¥2,940,000.00 from minority shareholders during the current period, consistent with the previous period[14] - The company’s major shareholders include Zhou Wei with 8.22% and Wang Ying with 4.96% of shares[46] - As of March 31, 2023, the company had repurchased 14,256,400 shares, representing 0.66% of the total share capital, with a total transaction amount of CNY 120.6238 million[54]

Financial Performance - The company reported a net profit of 108.44 million yuan for the year 2022, a decrease of 71.33% year-on-year, primarily due to macroeconomic impacts and delays in order fulfillment and project delivery [29]. - The total revenue for 2022 was reported at 1.2 billion RMB, representing a year-over-year increase of 15% [39]. - The net profit attributable to shareholders for 2022 was 150 million RMB, a decrease of 10% compared to the previous year [46]. - The gross margin for 2022 was reported at 45%, a slight decrease from 48% in 2021 due to increased operational costs [46]. - The company has set a performance guidance for 2023, targeting a revenue growth of 18% and a net profit margin of 12% [39]. - The company reported a significant increase in active users, reaching 5 million, up from 4 million in 2021, marking a 25% growth [39]. - The net profit attributable to shareholders decreased by 71.33% to CNY 108.44 million from CNY 378.17 million in the previous year [62]. - The net profit after deducting non-recurring gains and losses was CNY 119.21 million, down 43.74% from CNY 211.90 million in 2021 [62]. - The net cash flow from operating activities was CNY 100.44 million, a decline of 72.71% compared to CNY 368.06 million in the previous year [62]. - Basic earnings per share fell by 71.27% to CNY 0.0507 from CNY 0.1765 in 2021 [62]. Investment and Funding - As of December 31, 2022, the total amount of raised funds used was 706.63 million yuan, with 332.18 million yuan utilized during the reporting period, leaving a balance of 275.73 million yuan in the special account [3]. - The company plans to allocate the raised funds of 191.673 million yuan from the "Internet Medical and Innovative Operation Service Project - Cloud Medical Project" entirely to the "WiNEX MY Project" to enhance its digital healthcare solutions [1]. - The company reported a total fundraising amount of 961.2096 million yuan, with 332.1758 million yuan utilized so far, representing 34.6% of the total [1]. - The company has committed to a new generation of smart medical products and cloud services project with a total investment of ¥49,000,000, of which ¥48,287,540.00 has been invested, achieving 98.55% of the investment progress [172]. Research and Development - Research and development expenses for 2022 were 120 million RMB, accounting for 10% of total revenue, with a focus on new healthcare technologies [39]. - The company emphasizes the importance of increasing R&D investment and closely monitoring industry trends to maintain core competitive advantages in user numbers and technology [15]. - R&D investment for the year was ¥625 million, constituting 20.22% of total revenue, with 47 new patents obtained [107]. - Research and development investment amounted to ¥625,518,769.72, representing 20.22% of operating revenue [159]. - The number of R&D personnel increased by 9.90% to 2,487, with a notable rise in master's degree holders by 35.95% to 208 [137]. Market Expansion and Strategy - The company aims to expand its market share in the digital health sector by leveraging the WiNEX series products and enhancing brand effect through localized marketing services [13]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 20% increase in user base [39]. - The company has upgraded its "dual-wheel drive" strategy to "1+X" strategy, focusing on digitalizing healthcare resources through the WiNEX product series and the WinDHP platform [74]. - The company is exploring potential acquisitions in the healthcare technology sector to enhance its service offerings and market share [39]. - The company is actively involved in the development of innovative healthcare services under the "Internet+" model, enhancing its competitive edge in the healthcare information sector [74]. Operational Challenges and Risks - The company faces significant risks related to ongoing operations and management challenges due to rapid expansion and market integration opportunities [28]. - The company has identified risks related to technology and product development, as well as intensified industry competition [1]. - The company is focusing on optimizing personnel and business structure to ensure sustainable and healthy development in the face of macroeconomic challenges [81]. Product Development and Services - The company plans to launch two new products in the next quarter, focusing on telemedicine and remote patient monitoring solutions [39]. - The new generation WiNEX product series received widespread acclaim from experts and users in the digital health field, supporting the development of digital hospitals and innovative healthcare models [79]. - The company has established a new generation of digital medical products to support hospitals in their digital transformation efforts [1]. - The company is actively involved in the construction of smart hospitals, collaborating with Shanghai Shenkang to promote unified systems and data management [79]. Government and Industry Context - The software and information technology service industry in China saw a total revenue of CNY 1.08 trillion in 2022, with a year-on-year growth of 11.2% [49]. - The National Health Commission has set clear tasks and action requirements for the development of a standardized health information system, emphasizing the importance of digitalization in public hospitals [70]. - The "14th Five-Year Plan" for national health information technology aims to enhance hospital information systems and promote cloud deployment of medical imaging data [68]. - The government has emphasized the integration of artificial intelligence in healthcare, exploring various applications such as intelligent diagnostic support and smart hospital management [69].

出席本次说明会的人员有：公司董事长周炜先生，董事、高级副 总裁、董事会秘书靳茂先生，财务总监王利先生，独立董事王蔚松先 生，保荐代表人樊愈波先生（如有特殊情况，参会人员会有调整）。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩 说明会提前向投资者征集相关问题，广泛听取投资者的意见和建议。 投 资 者 可 于 2023 年 4 月 26 日 17:00 前 通 过 访 问 全 景 网 （http://ir.p5w.net/zj/）或扫描下方二维码进入问题征集专题页 面提出相关问题。公司将在2022年度业绩说明会上对投资者普遍关注 的问题进行回答。此次活动交流期间，投资者仍可登陆活动界面进行 互动提问。 欢迎广大投资者积极参与。 证券代码：300253 证券简称：卫宁健康 公告编号：2023-043 卫宁健康科技集团股份有限公司 关于举行 2022 年度业绩网上说明会并征集相关问题的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）定于2023 年4月27日（星期四）15:00-17:00在全景网 ...